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Abstract  
Due to the drop in sequencing cost, the number of sequenced genomes is increasing rapidly. 
To improve power of rare variant tests, these sequenced samples could be used as external 
control samples in addition to control samples from the study itself. However, when using 
external controls, possible batch effects due to the use of different sequencing platforms or 
genotype calling pipelines can dramatically increase type I error rates. To address this, we 
propose novel summary statistics based single and gene- or region-based rare-variant tests 
that allow the integration of external controls while controlling for type I error. Our approach 
is based on the insight that batch effects on a given variant can be assessed by comparing 
odds ratio estimates using internal controls only vs. using combined control samples of 
internal and external controls. From simulation experiments and the analysis of data from age 
related macular degeneration and type 2 diabetes studies, we demonstrate that our method can 
substantially improve power while controlling for type I error rate.  
Key words: Rare variant test; External controls; Next generation sequencing  
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Introduction 
Identification of genetic variants that predispose to complex diseases is an essential step toward 
understanding disease etiology, which can lead to breakthroughs in diagnosis, prevention, and 
treatment. The advance of sequencing technologies (Shendure & Ji, 2008) enables studying the full 
spectrum of genetic variants, including rare variants (minor allele frequency (MAF) < 1%), in large 
studies. Although recent sequencing studies have started to identify disease-associated rare variants 
(Cruchaga et al., 2014; Steinthorsdottir et al., 2014), the number of discoveries is much smaller than 
initially predicted (Zuk et al., 2014). To facilitate further discoveries, more efficient and powerful 
statistical strategies and methods are needed. 
Given decreasing sequencing costs, the number of sequenced whole exomes and even whole 
genomes are rapidly increasing. These sequenced samples provide a great opportunity to increase the 
power of rare variant test. For a single study, if sequenced samples from other studies are used as 
control samples (external control samples), the power of rare variant tests can be substantially 
improved without any additional sequencing cost. For example, using 1,529 external control samples 
from NHLBI GO Exome Sequencing Project (ESP) data in addition to their own 789 internal control 
samples, Zhan et al. (2013) identified a rare coding variant (MAF=0.4%, p-value=2.7×10
-4
) in the C3 
gene associated with age-related macular degeneration. When they exclusively used internal controls, 
the variant was substantially less significant.  
 Although the use of external control samples can greatly improve power, systematic 
differences between studies can have a negative impact on type I error control and power. 
Study heterogeneity can arise from differences in study populations, i.e. population 
stratification, or technical batch effects due to the use of different sequencing platforms or 
genotype calling pipelines (Quail et al., 2012). Recently, substantial progress has been made 
in identifying external control samples with similar genetic background (Bodea et al., 2016; 
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Wang et al., 2014); however, only limited success has been made in adjusting for technical 
batch effects. Derkach et al. (2014) developed a robust score test that uses genotype 
likelihoods. The method can control type I error rates when locations of variants are correctly 
known; however, inflated type I error rates are noted when variant locations should be 
inferred from genotype calls (Hu, Liao, Johnston, Allen, & Satten, 2016). More recently, Hu 
et al. (2016) developed a likelihood-based burden test that uses sequence reads, which can 
provide more accurate type I error rate controls. However, given that raw high depth 
sequence read data can be > 1000 times larger than processed genotype data, downloading, 
storing, and analyzing external control sequence read data can be a huge computational 
burden. In addition, the aforementioned methods need individual-level genotype and 
phenotype information, which is often difficult to obtain.  
 To address these challenges, we propose simple and robust rare variant association 
tests that only require allele counts from external studies. Our approach, integrating External 
Controls into Association Test (iECAT), is based on the insight that the existence of batch 
effects on a given variant can be assessed by comparing two different odds ratio estimates: 
odds ratio estimate using internal controls only vs. odds ratio estimate using combined 
control samples of internal and external controls. If a variant is subject to batch effects, these 
two should be substantially different; even when ancestry-matched external controls were 
used (Mahajan & Robertson, 2015). In such a case, only internal control samples should be 
used to avoid false positives. Otherwise, external control samples can be added to increase 
the sample size. To approach this problem data-adaptively, we propose using an empirical 
Bayesian-type method. We first construct a single variant test based on the shrinkage method 
and extend it to several gene- or region-based tests, such as burden tests (Li & Leal, 2008; 
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Madsen & Browning, 2009; A. P. Morris & Zeggini, 2010), variance-component tests (Wu et 
al., 2011), and combinations of these two (e.g. SKAT-O (Lee, Wu, & Lin, 2012)).  
 Given that only allele counts from external studies are needed for the proposed 
method, the method can be used with summary information publicly available in variant 
servers, such as the ESP data on the Exome Variant Server (ESP). Through extensive 
simulation studies and analysis of AMD and type 2 diabetes sequencing data, we demonstrate 
that the proposed method can improve power while controlling for type I error rates.  
 
Material and Methods 
Single variant association test 
For a single-variant test, we consider the following shrinkage estimation-based allelic test with an 
assumption that the Hardy-Weinberg equilibrium (HWE) holds. Let Y=1 (Y=0)  
denote affected (unaffected) status, G=1 (G=0) denote the minor allele (major allele) in the variant. 
Let n
I
0 and n
I
1 (n
E
0 and n
E
1) denote the number of controls and cases of an internal study (external 
study), respectively. The data are represented by a 3 x 2 table in Table 1.  
Considering the internal study only, let p
I
y denote the unknown true minor allele frequency 
(i.e., p
I
y = Pr[G=1|Y=y] for y=0, 1), and r
I
y denote the corresponding observed number of minor 
alleles. The observed counts can be viewed as a random sample from two independent binomial 
distributions, r
I
0 ~ Binomial(2n
I
0, p
I
0) and r
I
1 ~ Binomial(2n
I
1, p
I
1). Note that the number of trials is two 
times n
I
0 (or n
I
1) since each sample consists of two copies of chromosomes. Suppose the parameter of 
interest is a log odds ratio of the genetic effect, given by  
β0 = log[p
I
1 (1- p
I
0)/ {p
I
0 (1- p
I
1)}]. 
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Our goal is to test whether H0: β0 =0 or not. By using the internal study only, β0 can be consistently 
estimated by  ̂    = log[r
I
1 (2n
I
0 - r
I
0) / { r
I
0 (2n
I
1 - r
I
1)} ]. 
Now, suppose n
E
0 external control samples are available, and assume the observed number of 
minor alleles, r
E
0, follows a binomial distribution with p
E
0, the proportion of the minor allele in the 
external controls, i.e., r
E
0 ~ Binomial(2n
E
0, p
E
0). Combining control samples from internal and external 
studies, the estimate of β0 is 
 ̂    = log[r
I
1 (2n
I
0 +2n
E
0 – r
I
0 – r
E
0) / {(r
I
0+r
E
0 )(2n
I
1– r
I
1)}]. 
When p
I
0 = p
E
0, indicating that no batch effect exists,  ̂    converges to β0 in probability. When p
I
0 ≠ 
p
E
0, however,  ̂    converges to a biased quantity,  β0,Com = log[p
I
1 (1- p0
Com
)/ { p0
Com
 (1- p
I
1)}], where 
p0
Com
 = n
I
0/( n
I
0+ n
E
0) p
I
0 + n
E
0/( n
I
0+ n
E
0) p
E
0. Thus, the bias can be quantified as θ = β0,Com - β0 = 
log[p
I
0(1- p0
 Com
)/{p0
 Com 
(1- p
I
0)}]. Taking it for granted that the bias would exist, we propose a bias-
adjusted estimate of β0 as follows.  
We first estimate the bias θ by using an empirical Bayesian approach. It begins with an 
estimate  ̂    ̂     ̂    that asymptotically follows a normal distribution N(θ,   
 )  where   
  is the 
variance of  ̂. To account for the uncertainty in the bias, we assume that θ is a random variable 
following a normal distribution N(0, ν), where the unknown hyperparameter, ν, reflects the magnitude 
of uncertainty by the batch effects. Note that the consistent estimator of ν from the marginal 
distribution of  ̂ is  ̂         ̂   ̂ 
  , where  ̂ 
  is an estimate of   
  (C. N. Morris, 1983). 
Recently Mukherjee and Chatterjee (2008) have proposed to use  ̂   ̂ , a more conservative 
estimator of ν. The main advantage of using  ̂  instead of  ̂  is that  ̂  provides a closed-form of 
variance estimator of the subsequent θ estimator. They also showed that there is essentially no loss of 
efficiency of using  ̂   Therefore, we propose to use  ̂ , and the resulting estimate of the posterior 
mean of θ is  ̃  
 ̂ 
 ̂   ̂ 
  ̂  Finally, the proposed estimator of β0 is  
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 ̂   ̂     ̃        ̂       ̂       
 ̂ 
 ̂   ̂ 
              (1) 
When   ̂ (i.e., the difference between  ̂    and  ̂   ) is large,   is close to one, and hence  ̂ becomes 
 ̂     In contrast, when   is close to zero due to a small  ̂,  ̂ is close to  ̂   . Regardless of the size of 
the true bias θ,  ̂ is an asymptotically unbiased estimator of β0 (Web Appendix A). The exact 
expression of the asymptotic variance of  ̂ can be found in the Web Appendix A. When   is large and 
hence close to one,  ̂ can have a larger variance than  ̂   . In this case, we propose to use  ̂    to 
achieve better power.  
If there is a prior information on when θ could be zero under the null hypothesis (i.e pI1= p
I
0), 
using     can increase power without inflating type I error rates. Suppose that observed MAFs of 
external controls (i.e. r
E
0 / 2n
E
0) is in between observed MAFs of cases and internal controls (i.e. r
I
y / 
2n
I
y), and hence  ̂    is closer to zero than  ̂    ( i.e. | ̂       ̂   |). Under the null hypothesis with 
the batch effects (i.e. p
I
1 = p
I
0 ≠ p
E
0), since observed MAFs converge to true MAFs, the probability to 
observe this phenomenon will converge to zero. This indicates that using     in this situation will 
not increase type I error rates. In contrast, using     in this situation will increase power especially 
when the external controls include case samples, since the case contamination will cause either p
I
1 < 
p
E
0  < p
I
0   or p
I
1 > p
E
0  > p
I
0   under the alternative hypothesis. And hence when this phenomenon 
occurs, we used     as a default value in simulation studies and real data analysis.  
 
Gene- or region-based test 
For gene- or region-based tests, we extend the proposed single-variant test in the previous section to 
burden, SKAT and SKAT-O type tests. The key idea is first to construct a single-variant score-type 
statistic for each variant using  ̂ and then to aggregate them using their weighted linear or quadratic 
sums. To aggregate association signals in each variant, the burden test uses a weighted linear sum of 
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score statistics, whereas SKAT uses a weighted quadratic sum of score statistics. The combined test, 
SKAT-O, uses a linear combination of the burden and SKAT test statistics.  
Suppose that a region being tested has p variant loci. For variant j, let   ̂  be the log odds ratio 
estimate in (1),  ̂  the standard error estimate, and qj the MAF estimate from the internal samples. In 
Web Appendix B, we show that a single variant score statistic is approximately proportional to the 
product of log odds ratio estimate, sample size and the genotype variance. Using this fact, we 
construct a score-type statistic for a single variant j as                 ̂ , where neff is the 
effective sample size, and propose the following test statistics: 
               ∑(    )
 
 
   
  (∑    
 
   
)
 
  
where wj is a weight for variant j, and ρ is a parameter between 0 and 1. Clearly, ρ=0 corresponds to 
the SKAT-type test, and ρ=1 corresponds to the burden-type tests. Note that QiECAT(ρ) has a similar 
form to the variance component test with the compound symmetric kernel structure proposed by Lee 
et al. (2012). More details on the test and p-value calculation are given in Web Appendix C. 
Burden type tests (i.e. ρ=1) are powerful when large percentage of variants are causal and 
effects are in the same direction. SKAT type tests (i.e. ρ=0) are powerful when heterogeneity is noted 
regarding effect sizes and the direction of the effects (Basu & Pan, 2011; Lee, Abecasis, Boehnke, & 
Lin, 2014). SKAT-O type tests combine burden and SKAT tests using the minimum p-values from a 
grid of ρ. We propose the following SKAT-O type combined test as  
                        , 
where P-value(ρ) is the p-value           with a given ρ. We used a grid of eight ρ values (0, 0.1
2
, 
0.2
2
, 0.3
2
, 0.4
2
, 0.5
2
, 0.5, 1) in simulation studies and real data analysis. This approach has been used 
in previous studies and shown to provide good performances in type I error control and power (Lee, 
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Teslovich, Boehnke, & Lin, 2013). P-values of QiECAT- O can be obtained using numerical integration, 
as described in Lee et al. (Lee et al., 2012). 
 
Type I error and power simulations 
We performed extensive simulation studies to evaluate the performance of the proposed iECAT 
method. To generate sequence information, we simulated 40,000 European-like and 40,000 African-
America-like haplotypes for 200 kbps using the coalescent simulator COSI with the calibrated 
demographic model (Schaffner et al., 2005). The binary phenotypes were generated from the 
following logistic regression model: 
                         
           (2)  
where Gcausal is a genotype matrix containing causal variants, and βcausal is a vector of the genetic effect 
coefficients. The intercept α0 was chosen for the disease prevalence of 0.05.  
We presumed that 3% of the variants had different MAFs between internal and external 
control samples due to batch effects, mimicking the level of the batch effects observed in the real data 
analysis (see Results section for details). For these variants, MAFs in external control samples were 
randomly generated from Uniform (0.1×q, 4×q), where q is the MAFs in internal study samples. To 
mimic realistic scenarios of population stratification between internal and external control samples, 
we generated 0% (no population stratification), 5% and 10% of external control samples from the 
African-American-like haplotypes. All other internal and remaining external control samples were 
simulated from the European-like haplotypes. 
We compared the following methods for a region-based test: 1) the proposed iECAT-O; 2) 
SKAT-O using the internal control only; 3) iECAT-O without adjusting for batch effects (iECAT-
ONoadj) – that is,  ̂ =  ̂    was always used regardless of the existence of the batch effects; 4) iECAT-
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O assuming that batch effect variants were known prior to the test (iECAT-OKnown) – that is,  ̂ =  ̂    
was used (i.e., τ is fixed with 1) in the presence of true batch effects. Otherwise,  ̂ =  ̂    was used 
(i.e., τ is fixed with 0). Since iECAT-OKnown was constructed given that variants subject to batch 
effects were fully known, iECAT-OKnown could reach the theoretical maximum power under the 
iECAT framework. Obviously, this batch effect information could not be known in real data. 
Therefore, iECAT-OKnown will be used only for power comparison to quantify the efficiency loss in 
iECAT-O due to the uncertainty in  . For a single variant test, we used aforementioned approaches 
(iECAT-O, iECAT-ONoadj and iECAT-OKnown) and the Wald test (internal controls only) with testing 
one variant at a time. 
For region-based tests, we randomly selected a 3 kbp region and tested for an association 
between variants in the region and the phenotypes. For very rare variants, the proposed methods 
cannot be used because  ̂ estimates can be unstable. We thus only used variants observed in both 
internal and external studies with internal study MAC > 3. For single variant tests, we randomly 
selected a variant and tested for an association between the variant and the phenotypes. 
In type I error simulations, phenotypes were generated from (2) with        =0. For each 
simulation, to evaluate type I error rates at genome-wide significance levels, we generated 10
7
 
datasets for region-based tests and 5×10
7
 datasets for single variant tests. Given that generating these 
large datasets was computationally intensive, we considered only two internal study sample sizes, 
moderate and large (Ninternal=4000 and 10,000). In each sample size, two different ratios of case-
control (1:1 and 2:1) were considered. The external control sample size (Nexternal) was set to be the 
same as the internal study sample size.  
For power simulations for gene-based tests, 5%, 10%, or 30% of rare variants (MAF < 1%) 
were assumed to be causal. In each setting, either all causal variants were risk-increasing or 80% of 
causal variants were risk-increasing (the remaining 20% were risk-decreasing). Given that it is 
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possible that rarer variants have larger effect sizes, we modeled log OR as a decreasing function of 
MAF. Specifically, β=c|log10(MAF)|. When 30% of variants were causal, we used c= log(2)/2, which 
led to OR=2 for a causal variant with MAF=1%. When 5% or 10% of rare variants were causal, we 
used c= log(4)/2 and c= log(3)/2 to compensate the decreased numbers of causal variants. For single 
variant tests, we evaluated power for testing a variant with MAF=(0.01, 0.005) and OR=2.  
To evaluate the power when external control samples contain samples with the disease of 
interest (i.e., case-contamination), we generated external control samples of which 0%, 5% and 10% 
were the diseased samples. Because 5% disease prevalence was noted, 5% contamination was 
equivalent to using the general population as external controls. In all power simulation scenarios, the 
external control sample size was the same as the internal study sample size (Nexternal=Ninternal). For each 
power simulation setting, we generated 5000 data sets. 
 
Real data analysis 
We applied our method to two sequence datasets while using 4300 ESP European samples as external 
controls: targeted sequencing data from the age-related macular degeneration (AMD) study (Zhan et 
al., 2013) and deep whole exome sequence data from the Genetics of Type-2 Diabetes (GoT2D) study 
(Fuchsberger et al., 2016). The AMD study sequenced 10 target loci spanning 56 genes (2.7 Mb in 
total). We downloaded 3350 mapped SRA files from dbGaP (Tryka et al., 2014) (phs000684.v1.p1), 
applied variant calling and QC procedures as described in Zhan et al. (2013), and retained 2317 cases 
and 791 controls. The GoT2D study whole exome sequenced 1,326 European T2D cases and 1,331 
European T2D controls at high depth. For both datasets, we applied LASER software with the HGDP 
reference (Wang et al., 2014) to identify population structure. Given that Finish samples were 
separately clustered from other European samples (Web Figure 8), and ESP has only a small number 
of samples clustered together with Finish samples (Web Figure 8), we exclusively used the non-Finish 
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cohorts (British, German and Sweden) in the GoT2D data analysis, leading to a total of 650 cases and 
646 controls.  
 For external controls, allele counts of ESP samples were downloaded from the ESP Exome 
Variant Sever. Variants observed in both internal and external studies were included in the analysis, 
after excluding variants that did not pass each study’s own QC criteria. We further excluded variants 
with internal study MAC ≤ 3. For gene-based tests, we used genes with at least 3 rare variants. To 
investigate whether ancestry matching can improve type I error control and power for whole exome 
scale data analysis, we obtained individual-level genotype data of ESP for the GoT2D data analysis. 
We used LASER software with the HGDP reference for 1:2 matching between internal and external 
samples and identified 2,568 ancestry-matched external control samples (Web Figure 8). 
 
Results 
Type I error rate simulation results 
The empirical type I error rates estimated for iECAT-O and the other methods are presented in Table 
2 for α = 10-4 and 2.5×10-6, corresponding to candidate gene studies of 500 genes and exome-wide 
studies of 20,000 genes. All internal and external samples were simulated using European-like 
haplotypes. In all the simulation scenarios we considered, iECAT-O had well controlled or slightly 
inflated type I error rates. As expected, when we used the combined control samples but ignored batch 
effects (iECAT-ONoadj), type I error rates were significantly inflated. For example, empirical type I 
error rates were increased more than 10000–fold compared to the nominal α level on average when α 
=2.5×10
-6
. When we exclusively used the internal control samples (SKAT-O), type I error rates were 
well controlled.  
 When only summary-level information for external control samples is available, samples 
with different genetic background cannot be excluded. We carried out additional type I error 
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simulations with 5% and 10% of external control samples from the African-American-like haplotypes, 
and the results have shown that iECAT-O had robust type I error control even in the presence of 
population stratification (Details See Web Appendix D).  
 
Power simulation results 
Next, we compared power of the proposed and existing methods to identify genetic associations at α = 
2.5×10
-6
. Figure 1 presents power simulation results when all causal variants were deleterious 
variants. iECAT-O had substantially improved power compared to the approach using internal study 
samples only. For example, when the internal study case-control ratio was 1:1 and the internal study 
sample size was 10,000, iECAT-O was on average 38% to 60% more powerful. When the internal 
study case-control ratio was 2:1, iECAT-O exhibited increased power. On average, when the internal 
study sample size was 10,000, the strategy to sequence more cases (2:1 case-control ratio compared to 
1:1) resulted in 11% to 17% increased power for iECAT-O compared to sequencing the same number 
of cases and controls (Figure 1, bottom panel). As expected, the power of iECAT-OKnown, where the 
optimal value of shrinkage weight   was used, was higher than that of iECAT-O, but the difference 
was not substantial. This implies that estimating   in iECAT-O method did not reduce the efficiency 
so much. Given that iECAT-ONoadj greatly increased type I error rates, we did not include it in this 
plot. The relative performance of the methods in the presence of both risk-increasing and risk-
decreasing variants was quantitatively similar (Web Figure 2).  
Given that external studies were not performed for the target disease of interest in the internal 
study, it is possible that external control samples included cases (i.e., the diseased samples), and this 
case-contamination can reduce the power. Figure 2 presents power evaluation results with 0%, 5% 
and 10% of the external control samples being cases. Given that 5% disease prevalence was assumed, 
5% contamination is equivalent to using the general population as external controls. When 
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Ninternal=10,000, the power was decreased on average by 2 to 4% for 5% contamination and 3 to 8% 
for 10% contamination. When the sample size was small, the power reduction was slightly larger.  
Next, we performed power simulations in the presence of population stratification between 
internal and external samples in which 5% and 10% of the external control samples were generated 
from African American-like haplotypes and all other samples were generated from European-like 
haplotypes. Given that population stratification can inflate type I error rates, we used empirical α 
levels obtained in the type I error simulation studies for fair comparisons. Web Figure 3 indicates that 
the power of iECAT-O slightly decreased in the presence of population stratification. These results 
suggest that the power of iECAT-O can be improved if the ancestry-based matching method is used to 
exclude external control samples with different genetic backgrounds.   
As expected, the power simulation results with for iECAT with ρ=0 (SKAT type test) and ρ=1 
(burden type of tests) were quantitatively similar (Web Figure 4-5). We obtained power with 
empirical α levels instead of nominal α levels for Ninternal =4000 and 10,000, and the results were also 
quantitatively similar (Web Figure 6). We then performed power simulations for single variant tests 
for two different MAFs (1% and 0.5%) (Web Figure 7). The power curves revealed that iECAT had 
greatly improved power compared with the method exclusively using internal controls (e.g., 43% vs. 
12% when MAF=0.5%, Ninternal=10,000 and case:control=1:1). Interestingly, the strategy of 
sequencing more cases (case:control=2:1) did not always improve the power compared with the one 
case per one control strategy. For example, when MAF=0.5% and Ninternal =15,000, case:control=2:1 
design had 72% power, while case:control=1:1 design  had 75% power. This occurred in part because 
having a smaller number of internal controls increased the variability of the bias estimate, which had a 
negative impact on power. We note that this increased variability had a smaller effect on gene-based 
tests given that the gene-based approach combines multiple single variant odds ratios.  
Overall, our simulation studies demonstrate that iECAT can substantially improve power 
compared with the existing approaches that exclusively use internal control samples, while controlling 
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for type I error in a wide range of scenarios. In contrast, if the external control samples are used 
without adjusting for batch effects, it can result in significantly increased type I error rates.  
 
Real data analysis 
We applied our proposed methods to the analysis of AMD targeted sequencing and GoT2D whole 
exome sequencing datasets. For both datasets, we used allele count statistics of 4300 ESP European 
samples downloaded from Exome Variant Server as external controls. In addition, for the GoT2D data 
analysis we obtained the ancestry-matched external control samples using individual-level genotype 
data of ESP to investigate whether matching can improve type I error control and power in whole 
exome scale analysis.   
 
AMD Study: We applied iECAT to 56 candidate genes in the AMD targeted sequencing dataset. After 
quality control, we retained 2317 cases and 791 controls. Table 3 presents the top 5 genes by iECAT-
O. For this analysis, we focused on rare variants (MAF < 1%). By combining the internal and external 
controls, iECAT-O revealed that two well-known AMD-related genes, C3 and CFH, had the smallest 
p-values (p-value=5.75×10
-6
 and p-value=7.44×10
-6
, respectively), and the p-values were still 
significant after the Bonferroni correction (corrected α= 0.05/56=8.9×10-4). In contrast, when SKAT-
O was performed with the AMD dataset alone, the p-values were greater than 0.01, indicating that the 
proposed test significantly improved power. We also performed single variant tests for a total of 538 
rare variants (Web Table 3). We found that SNV rs147859257 in C3 (p-value = 1.23×10
-5
) and 
rs121913059 in CFH (p-value=1.24×10
-5
) were the top two variants by iECAT. However, when the 
AMD dataset was used alone, these two SNVs resulted in p-values > 10
-2
. The single variant test 
results were largely consistent with Zhan et al. (2013), in which 1529 ancestry-matched external 
controls were used.  
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GoT2D Study: We performed single variant and gene-based tests with GoT2D deep exome 
sequencing data. Given that the ESP dataset contains few Finish samples (see Method), we focused on 
non-Finish GoT2D cohorts in this analysis, which included 650 cases and 646 controls. The gene-
based rare-variant test results are summarized through QQ plots in Figure 3 (top panel); the iECAT-O 
QQ plot was fairly well calibrated. In contrast, iECAT-ONoadj resulted in a significantly inflated QQ-
plot. Even after the external control samples were ancestry matched (a total of 2568 external control 
samples; Web Figure 8), the QQ-plot by iECAT-ONoadj remained significantly inflated, which suggests 
that technical batch effects were a major source of the type I error inflation (Figure 3, bottom panel). 
In contrast, iECAT-O had a well-calibrated QQ plot. Figure S9 compares p-values calculated with all 
4300 ESP external control samples and 2568 ancestry-matched external control samples. These two p-
values were largely consistent, indicating that iECAT-O analyses with and without ancestry-based 
matching were largely similar in this dataset. 
We also performed single variant tests (Web Figure 10) for low frequency and rare variants 
with MAF < 5%. As expected, QQ plots of iECAT were well calibrated, whereas QQ plots of 
iECATNoadj were greatly inflated. When we compared allele frequencies between the internal control 
samples and the matched external control samples, approximately 13% and 23% variants had p-values 
< 10% and 20%, respectively. These 3% inflation may indicate that approximately 3% of variants 
were subject to technical batch effects. To investigate whether the batch effects vary by minor allele 
counts (MAC), we obtained a distribution of the shrinkage weight   by MAC (Web Figure 11). The 
box plots were similar across all four MAC bins, indicating that there was no clear pattern in batch 
effects by MAC. 
Web Table 4 presents the top 5 genes by iECAT-O. Although GoT2D analysis did not 
identify statistically significant T2D-associated genes, this analysis provided a suggestive association 
and demonstrated that the proposed approach can control for type I errors.  
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Discussion 
In this paper, we proposed rare variant tests that increase power by integrating external control 
samples. By estimating bias using an Empirical Bayesian approach, the proposed iECAT method 
provides an effective way to adjust for possible batch effects. The type I error simulation and GoT2D 
data analysis revealed that iECAT can control for type I errors in the presence of technical batch 
effects. The power simulation and AMD data analysis revealed that iECAT can improve power 
compared with the exclusive use of internal controls. The method is implemented in the iECAT R 
package (available on the author's website). 
  One of the important features of iECAT is that it only needs allele counts from external 
studies. By utilizing allele count information readily available in variant servers, such as Exome 
Variant Server (ESP) and  ExAC browser (Lek et al., 2016), our method can greatly facilitate the use 
of external control samples. This is a desirable property considering the difficulties in obtaining 
individual-level genotype data. One possible issue of using allele count information in a variant server 
is that we cannot filter out samples with different genetic background. In such case, iECAT could 
yield slightly inflated type I error rates. We believe that it will become less problematic in the future 
as variant servers are starting to provide allele counts for fine-scale ancestry. 
 There are several limitations in the present proposal. First, the proposed method cannot adjust 
for covariates such as age, gender and principal components. In Web Appendix E, we present a simple 
approach that can adjust for covariates by estimating covariate-adjusted minor allele counts. The 
approach is similar to the principal component adjustment method used in EigenStrat (Price et al., 
2006), and a small-scale simulation study shows that the method can adjust for population 
stratification when the population index was used as a covariate. The presented approach, however, 
requires individual-level genotype and phenotype data from external controls. Second, the proposed 
method mainly assumed that one external study is used for external controls. If multiple study data are 
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used as external controls, it is possible that there exist multiple batch effects. One possible way to 
addressing it is to apply the covariate adjustment in Web Appendix E to adjust for batch effects in the 
external control genotypes and to use adjusted minor allele count for the association tests. Third, the 
method assumes that HWE holds (Guedj, Nuel, & Prum, 2008). Since it is uncommon to observe rare 
allele homozygotes, the violation of HWE condition would have limited effects on the proposed tests. 
Fourth, we do not recommend using the method for singletons or doubletons because log odds ratio 
estimates can be unstable for these variants. In future work, we will extend the method to incorporate 
singletons and doubletons.  
With the advances in sequencing technologies, the number of sequenced genomes is 
increasing rapidly. Our method provides a robust and effective way to utilize these sequenced 
genomes in rare variant tests and will contribute to the understanding of the genetic architecture of 
complex diseases.  
 
Supplemental Data 
Supplemental Data are comprised of web appendices, four tables and eleven figures. 
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Figure Legend 
Figure 1. Power comparisons when all causal variants were risk increasing variants 
Each line represents empirical power at α = 2.5×10-6. From left to right, the plots consider that 5%, 
10%, and 30% of variants were causal variants, respectively. From top to bottom the plots consider 
that internal study case:control ratio was 1:1 and 2:1, respectively. The external control sample sizes 
were the same as the internal study sample sizes. For causal variants, we assumed that β = 
c|log10(MAF)| (See Method section). 
Figure 2. Empirical power of iECAT-O in the presence of case-contamination in external 
controls 
Each line represents empirical power at α = 2.5×10-6. From left to right, the plots consider that 5%, 
10%, and 30% of variants were causal variants, respectively. From top to bottom the plots consider 
that internal study case:control ratio was 1:1 and 2:1, respectively. All causal variants were risk-
increasing variants. The external control sample sizes were the same as the internal study sample size. 
For causal variants, we assumed that β = c|log10(MAF)| (See Method section). 
Figure 3.  Analysis of the GoT2D exome data with ESP as external control samples  
QQ-plots of -log10 p-values of gene-based tests for rare variants (MAF < 1%). A total of 11283 genes 
with at least three rare variants were tested for associations with T2D status. The dashed line 
represents a 95% confidence band. Top panel: all 4300 European ESP samples were used as external 
controls. Bottom panel: 2568 ancestry matched ESP samples were used as external controls.  
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Table 1. Data setup for internal case-control and external control samples for a single variant 
association test.  
 
  Gj=1 Gj=0 Total 
Internal Y=1 r
I
1 2n
I
1 - r
I
1 2n
I
1 
 Y=0 r
I
0 2n
I
0 - r
I
0 2n
I
0 
External Y=0 r
E
0 2n
E
0 - r
E
0  2n
E
0 
 
Table 2. Empirical type I error rates for iECAT-O, SKAT-O and iECAT-ONoadj. Each cell has an 
empirical type I error rate estimated from 10
7
 simulated datasets.  The external control sample sizes 
were the same as the internal sample sizes. All internal and external controls samples were simulated 
from European-like haplotypes. 
 
Internal 
Sample Size 
Internal 
Case:Control Level α iECAT-O SKAT-O iECAT-ONoadj 
4000 1:1 10
-4
  7.40E-05 1.10E-04 7.00E-02 
 1:1 2.5×10
-6
 1.40E-06 2.10E-06 5.50E-02 
 2:1 10
-4
  8.00E-05 1.20E-04 8.40E-02 
 2:1 2.5×10
-6
 2.60E-06 2.10E-06 7.00E-02 
10000 1:1 10
-4
  8.60E-05 1.10E-04 1.10E-01 
 1:1 2.5×10
-6
 3.50E-06 2.90E-06 9.30E-02 
 2:1 10
-4
  8.70E-05 1.10E-04 1.20E-01 
 2:1 2.5×10
-6
 2.40E-06 3.10E-06 1.10E-01 
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Table 3.  Top five genes by iECAT-O p-values from the AMD data analysis. The 4300 European ESP 
samples were used as external controls. Rare variants (MAF < 1%) were exclusively used for this 
analysis.  
 
Gene 
 
Chr 
 
# of variant*  
iECAT-O 
P-values 
SKAT-O 
P-values 
CFH 1 14 5.75E-06 6.70E-02 
C3 19 27 7.44E-06 1.04E-02 
DOM3Z 6 7 1.16E-04 1.69E-03 
CFHR4 1 6 8.03E-04 6.66E-02 
SLC44A4 6 16 1.39E-03 4.47E-02 
* Variants with internal study MAC ≤ 3 were excluded from the analysis.  
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